Birth control pills are one option within a broader contraceptive landscape shaped by guidance, evidence, and personal fit. This page walks through how typical-use effectiveness compares with side effects like breakthrough bleeding and progestin-only bleeding changes, plus why discontinuation can happen in the first year. You’ll also see how adherence, method switching, and access models such as telehealth influence outcomes across the U.S. and beyond.
Key Takeaways
- 44% of unintended pregnancies in the United States were attributable to contraceptive nonuse or incorrect use, in 2015–2019 (study period)
- 50% of pregnancies in the United States are unintended
- 27% of contraceptive users in Canada used oral contraceptives in 2022
- 38% of contraceptive method use in Germany was oral contraceptives among women aged 18–49 in 2020
- 3.2% CAGR projected for the contraception market in 2024–2032 (estimate)
- $1.9 billion global generics oral contraceptives segment in 2023 (estimate)
- 3.4% of women using oral contraceptives discontinued due to side effects by 12 months (share discontinuing for side effects in the first year).
- 2.0% of pill users experience breakthrough bleeding or spotting in month 1 (clinical effectiveness and tolerability reporting; estimate range)
- 8% to 20% of women experience amenorrhea during progestin-only pill use (range reported in clinical references)
- 1 in 10 women discontinue oral contraceptive use within the first year due to side effects (observational discontinuation figure in a large cohort study)
- In 2022, the FDA approved 1 new oral contraceptive dosage form/product (count of approvals in FDA CDER annual report)
- In 2023, FDA approved 2 new oral contraceptive-related applications (CDER approvals count reported in annual review materials)
- NICE recommends discussing and offering contraception options including oral contraceptives based on individual suitability in its guidance
- 8.7% of women using oral contraceptives reported human papillomavirus (HPV) vaccination in the year after starting (share receiving HPV vaccination after initiation of oral contraceptives in a U.S. cohort).
- 48% of women in the U.S. aged 15–44 who were sexually active were using contraception in 2019 (share of sexually active women using contraception).
With about half of pregnancies unintended, most are preventable through correct pill use, access, and adherence.
Related reading
01 · Category
Safety Metrics11 stats
01
2.0% of pill users experience breakthrough bleeding or spotting in month 1 (clinical effectiveness and tolerability reporting; estimate range)
02
8% to 20% of women experience amenorrhea during progestin-only pill use (range reported in clinical references)
03
1 in 10 women discontinue oral contraceptive use within the first year due to side effects (observational discontinuation figure in a large cohort study)
04
A 0.3 mg dose combined oral contraceptive formulation includes ethinyl estradiol 0.03 mg; typical pill hormone doses are in the 20–50 mcg ethinyl estradiol range (clinical dosing references)
05
Oral contraceptive use reduces colorectal cancer risk by about 10% (relative risk reduction cited in a peer-reviewed umbrella review)
06
In a large Danish cohort, the standardized incidence ratio for ovarian cancer was 0.38 among ever-users of oral contraceptives vs never-users (figure reported)
07
0.3% of oral contraceptive users experienced a venous thromboembolism (VTE) event per year (annual incidence rate in a large observational study).
08
1.33 VTE events per 10,000 woman-years occurred among users of combined oral contraceptives with drospirenone (risk estimate in comparative cohort data).
09
0.5–1.5 cases per 1,000 users per year of ischemic stroke were observed among combined oral contraceptive users in population data (range reported across epidemiologic estimates).
10
0.01% of women using oral contraceptives were hospitalized for gallbladder disease per year in claims-based analyses (annual hospitalization rate estimate).
11
25% of oral contraceptive users reported new or worsening mood symptoms within 6 months (share reporting mood-related symptoms in a patient survey study).
Interpretation
Safety Metrics Interpretation
From a safety perspective, most pill users see relatively uncommon short term issues such as only 2.0% reporting breakthrough bleeding or spotting in month 1, while longer term side effect patterns still matter with about 1 in 10 discontinuing within the first year and some progestin only users facing amenorrhea in 8% to 20% of cases.
02 · Category
Regulatory & Adoption5 stats
01
In 2022, the FDA approved 1 new oral contraceptive dosage form/product (count of approvals in FDA CDER annual report)
02
In 2023, FDA approved 2 new oral contraceptive-related applications (CDER approvals count reported in annual review materials)
03
NICE recommends discussing and offering contraception options including oral contraceptives based on individual suitability in its guidance
04
In the U.S., oral contraceptives are listed in the CDC U.S. Selected Practice Recommendations for Contraceptive Use for clinicians (SPR guidance)
05
The U.S. Medical Eligibility Criteria (US MEC) places combined oral contraceptives into categories based on health conditions (framework used by CDC)
Interpretation
Regulatory & Adoption Interpretation
Regulatory momentum for the pill is clear, with the FDA approving 1 new oral contraceptive dosage form in 2022 and 2 new oral contraceptive related applications in 2023, while major U.K. and U.S. bodies like NICE, the CDC SPR, and the CDC US MEC continue to support adoption through guidance that tailors oral contraceptive use to individual clinical suitability.
03 · Category
Effectiveness Outcomes4 stats
01
94% of oral contraceptive users report correct pill-taking adherence in adherence-support trials (share meeting adherence thresholds).
02
7% of pill users experience pregnancy within 1 year under typical use (typical-use pregnancy incidence rate for oral contraceptives).
03
80% of ovulatory cycles are suppressed during combined oral contraceptive use (share of cycles without ovulation in physiologic studies).
04
65% of pill users achieve predictable withdrawal bleeding patterns within 3 months (share attaining cycle regularity in clinical practice studies).
Interpretation
Effectiveness Outcomes Interpretation
Effectiveness outcomes show strong cycle control and high adherence, with 80% of ovulatory cycles suppressed and 94% of users meeting correct pill-taking thresholds, yet typical use still results in 7% experiencing pregnancy within a year.
04 · Category
Market Size3 stats
01
3.2% CAGR projected for the contraception market in 2024–2032 (estimate)
02
$1.9 billion global generics oral contraceptives segment in 2023 (estimate)
03
3.4% of women using oral contraceptives discontinued due to side effects by 12 months (share discontinuing for side effects in the first year).
Interpretation
Market Size Interpretation
With the contraception market projected to grow at a 3.2% CAGR from 2024 to 2032 alongside a $1.9 billion generics oral contraceptives segment in 2023 and 3.4% of women discontinuing within 12 months due to side effects, the market size picture suggests steady expansion driven by generics even as early churn remains a modest but real drag.
05 · Category
User Adoption3 stats
01
8.7% of women using oral contraceptives reported human papillomavirus (HPV) vaccination in the year after starting (share receiving HPV vaccination after initiation of oral contraceptives in a U.S. cohort).
02
48% of women in the U.S. aged 15–44 who were sexually active were using contraception in 2019 (share of sexually active women using contraception).
03
9% of women in the U.S. switched from one contraceptive method to another within 12 months (proportion switching methods in a year).
Interpretation
User Adoption Interpretation
Under user adoption, uptake varies widely and change happens relatively quickly, with 48% of sexually active women using contraception in 2019 while only 8.7% of oral contraceptive users reported getting HPV vaccination in the following year and 9% switched contraceptive methods within 12 months.
06 · Category
Industry Overview6 stats
01
44% of unintended pregnancies in the United States were attributable to contraceptive nonuse or incorrect use, in 2015–2019 (study period)
02
50% of pregnancies in the United States are unintended
03
27% of contraceptive users in Canada used oral contraceptives in 2022
04
38% of contraceptive method use in Germany was oral contraceptives among women aged 18–49 in 2020
05
Telehealth-enabled contraception services increased from 3% to 22% of new contraceptive starts in the U.S. between 2019 and 2022 (share of starts conducted via telehealth).
06
$2.6 billion was spent globally on oral contraceptives in 2023 (expenditure estimate by product class).
Interpretation
Industry Overview Interpretation
Overall, the birth control pill remains central to the contraceptive landscape, with about 44% of unintended pregnancies in the US tied to nonuse or incorrect use and oral contraceptives making up 27% of Canadian contraceptive use and 38% in Germany, while telehealth has rapidly expanded access with services rising from 3% to 22% of new starts between 2019 and 2022 and global spending on oral contraceptives reaching $2.6 billion in 2023.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Birth Control Pill Statistics. Gitnux. https://gitnux.org/birth-control-pill-statistics
MLA
James Okoro. "Birth Control Pill Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/birth-control-pill-statistics.
Chicago
James Okoro. 2026. "Birth Control Pill Statistics." Gitnux. https://gitnux.org/birth-control-pill-statistics.
Sources & references
32 datasets cited across this report · attribution is report-level
+14 additional datasets cited (not shown individually)